At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
BI 1569912 +3 moredrug
Likely dose
Repaglinide 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Multiple Doses of BI 1569912 on the Single-dose Pharmacokinetics of Repaglinide, Midazolam and Bupropion Following Oral Administration in Healthy Male and Female Subjects (an Open-label, 2-period Fixed-sequence Trial)
In Brief
A Phase 1 clinical trial evaluating BI 1569912, Repaglinide, and 2 other interventions for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e. sensitive CYP2C8, CYP3A4 and CYP2B6 substrates).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedApr 2024
Enrollment StartMay 2024
Primary CompletionAug 2024
TodayJul 2026
First PostedApr 16, 2024
Enrollment StartMay 15, 2024
Primary CompletionAug 20, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.2 years ago
Interventions
BI 1569912drug
Intended dose of BI 1569912
Repaglinidedrug
0.5 mg tablet
Midazolamdrug
2 mg solution for injection
Bupropiondrug
150 mg extended-release tablet